Tourette syndrome

Boston Scientific Launches Vercise™ Primary Cell And Vercise Gevia™ Deep Brain Stimulation Systems With Directional Leads

Retrieved on: 
목요일, 1월 24, 2019
Medicine, Electromagnetism, Neurotechnology, Electrotherapy, Clinical medicine, Neuroprosthetics, Medical devices, Deep brain stimulation, Tourette syndrome, Electrode, Rechargeable battery, DBS

MARLBOROUGH, Mass., Jan. 24, 2019 /PRNewswire/ --Boston Scientific Corporation (NYSE: BSX) has launched the Vercise Primary Cell (PC) and Vercise Gevia Deep Brain Stimulation (DBS) Systems featuring the Vercise Cartesia Directional Lead.

Key Points: 
  • MARLBOROUGH, Mass., Jan. 24, 2019 /PRNewswire/ --Boston Scientific Corporation (NYSE: BSX) has launched the Vercise Primary Cell (PC) and Vercise Gevia Deep Brain Stimulation (DBS) Systems featuring the Vercise Cartesia Directional Lead.
  • The Vercise Cartesia Directional Lead was the first directional lead introduced to the global market when it launched in Europe in 2015.
  • The new systems featuring the Vercise Cartesia Directional Lead leverage eight individually controlled electrodes on each lead to offer stimulation that can adapt to impedance changes within the brain.
  • "The newly approved Vercise Directional DBS Systems offer smaller devices, are engineered for longer rechargeable battery life and more customizable stimulation compared to other similar systems currently in the market.

Neurocrine Biosciences Announces Topline Data from Phase IIb T-Force GOLD Study Demonstrating Valbenazine Did Not Meet Primary Endpoint in Pediatric Patients with Tourette Syndrome

Retrieved on: 
수요일, 12월 12, 2018
Tourette syndrome, Psychiatric diagnosis, Medicine, Health

"We are very disappointed with the topline data from the T-Force GOLD study given that children and adolescents with Tourette syndrome need better treatment options.

Key Points: 
  • "We are very disappointed with the topline data from the T-Force GOLD study given that children and adolescents with Tourette syndrome need better treatment options.
  • We will further analyze the data to determine the next steps for valbenazine in Tourette syndrome."
  • The T-Force GOLD study was a multicenter, randomized, double-blind, placebo-controlled, parallel group, Phase IIb study to evaluate the safety, tolerability and efficacy of once-daily valbenazine capsules in 127 pediatric patients with moderate to severe Tourette syndrome.
  • The primary endpoint of T-Force GOLD was the change from baseline of the YGTSS Total Tic Score at week 12.

Neurocrine Biosciences Reports Third Quarter 2018 Financial Results

Retrieved on: 
월요일, 11월 5, 2018
RTT, Gynaecological neoplasia, Uterine fibroid, Health, AbbVie Inc., Tourette syndrome, Medicine, Clinical medicine, Neurocrine Biosciences

Sales, general and administrative (SG&A) expenses increased to $60.4 million for the third quarter of 2018 from $43.9 million for the third quarter of 2017.

Key Points: 
  • Sales, general and administrative (SG&A) expenses increased to $60.4 million for the third quarter of 2018 from $43.9 million for the third quarter of 2017.
  • In the second quarter of 2018, the Company commenced enrollment into the open-label extension study, T-Force GOLD Plus, for pediatric patients with Tourette syndrome.
  • In the second quarter of 2018, the Company started T-Force PLATINUM, a double-blind, placebo-controlled, randomized withdrawal study of valbenazine in pediatric patients with Tourette syndrome.
  • AbbVie provided positive top-line efficacy data from two Phase III studies in women with uterine fibroids in the first quarter of 2018 and from the associated six-month safety extension during the third quarter of 2018.

Dollars 4 Tic Scholars Announces 2018 Scholarship Recipients

Retrieved on: 
목요일, 6월 28, 2018
Human behavior, Tourette syndrome, Psychiatric diagnosis, Brad Cohen, Tic

The six scholarship recipients include:

Key Points: 
  • The six scholarship recipients include:
    Dakota Austin Eads of Cape Coral, FL -- Recipient of the "2018 Dollars 4 Tic Scholars Tourette Syndrome Graduate Student Scholarship" in the amount of $1,500.00.
  • Rachel Elena Keener of Midlothian, TX -- Recipient of the "2018 Dollars 4 Tic Scholars Tourette Syndrome Scholarship Sponsored by the Brad Cohen Tourette Foundation " in the amount of $1,000.00.
  • Jacob Malloy Fleming of Tampa, FL -- Recipient of the "2018 Dollars 4 Tic Scholars Tourette Syndrome Scholarship" in the amount of $1,000.00.
  • The Dollars 4 Tic Scholars scholarship program received scholarship applications from students around the country in response to its offering.

Khiron Forms Exclusive Strategic Alliance with ILANS, Expanding Distribution Network to Over 500,000 Patients

Retrieved on: 
목요일, 6월 14, 2018
Medicine, Herbalism, Medicinal plants, Health, Clinical medicine, Antiemetics, Antioxidants, Medical cannabis, Pharmaceuticals policy, Tourette syndrome, Chronic condition, Cannabis

ILANS represents an estimated 100,000 patients, with the majority of these patients being located in Colombia.

Key Points: 
  • ILANS represents an estimated 100,000 patients, with the majority of these patients being located in Colombia.
  • Alvaro Torres, Chief Executive Officer of Khiron, stated, "This exclusive strategic alliance with ILANS represents a significant increase in the size of the potential patient base for Khiron.
  • The alliance provides for research, technological product development, and evaluation and commercialization of products related to all aspects of medical cannabis.
  • Referral arrangements for treatment of patients with chronic pain, epilepsy, post-chemotherapy nausea, sleep disorders, Parkinson's disease, Tourette's syndrome, and multiple sclerosis.

Therapix Biosciences Sponsors the 2018 Annual Meeting of the European Society for the Study of Tourette Syndrome

Retrieved on: 
월요일, 6월 11, 2018
Tourette syndrome, Acetylcholinesterase inhibitors, Antiemetics, Appetite stimulants, Entheogens, Medicine, James F. Leckman, Palmitoylethanolamide, Yale Child Study Center, Dronabinol, Health, Psychiatry

Dr. Bloch, an Associate Professor at the Yale University Child Study Center, the investigator-initiator of the trial, and a member of the Company's scientific advisory board committee.

Key Points: 
  • Dr. Bloch, an Associate Professor at the Yale University Child Study Center, the investigator-initiator of the trial, and a member of the Company's scientific advisory board committee.
  • The study, suggesting that the proprietary cannabinoid combination THX-110 [which is a combination of dronabinol (-9-tetrahydracannabinol) and palmitoylethanolamide (PEA)] showed significantly improved symptoms over time in adult subjects with Tourette syndrome ( link to press release ).
  • The study was led together with James F. Leckman, M.D., Ph.D., of the Neison Harris Professor in the Child Study Center and Professor of Pediatrics Child Psychiatry at Yale University.
  • Therapix Biosciences Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of Senior Executives and Scientists.